CA2364251A1 - Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs - Google Patents

Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs Download PDF

Info

Publication number
CA2364251A1
CA2364251A1 CA002364251A CA2364251A CA2364251A1 CA 2364251 A1 CA2364251 A1 CA 2364251A1 CA 002364251 A CA002364251 A CA 002364251A CA 2364251 A CA2364251 A CA 2364251A CA 2364251 A1 CA2364251 A1 CA 2364251A1
Authority
CA
Canada
Prior art keywords
long
viral replication
nucleoside analogs
chain hydrocarbons
synergistic inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002364251A
Other languages
French (fr)
Other versions
CA2364251C (en
Inventor
John F. Marcelletti
Laura E. Pope
Mohammed H. Khalil
David H. Katz
Lee R. Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avanir Pharmaceuticals Inc
Original Assignee
John F. Marcelletti
Laura E. Pope
Mohammed H. Khalil
David H. Katz
Lee R. Katz
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John F. Marcelletti, Laura E. Pope, Mohammed H. Khalil, David H. Katz, Lee R. Katz, Avanir Pharmaceuticals filed Critical John F. Marcelletti
Publication of CA2364251A1 publication Critical patent/CA2364251A1/en
Application granted granted Critical
Publication of CA2364251C publication Critical patent/CA2364251C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention is related to antiviral compositions comprising long-chain aliphatic compounds in combination with a nucleoside analog or phosphonoformic acid, in a pharmaceutically acceptable carrier. Methods for treating viral infections using such compositions are also disclosed.
CA002364251A 1999-03-10 2000-03-08 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs Expired - Fee Related CA2364251C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/265,922 1999-03-10
US09/265,922 US6440980B1 (en) 1996-09-17 1999-03-10 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
PCT/US2000/005965 WO2000053167A2 (en) 1999-03-10 2000-03-08 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs

Publications (2)

Publication Number Publication Date
CA2364251A1 true CA2364251A1 (en) 2000-09-14
CA2364251C CA2364251C (en) 2004-11-02

Family

ID=23012439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364251A Expired - Fee Related CA2364251C (en) 1999-03-10 2000-03-08 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs

Country Status (20)

Country Link
US (2) US6440980B1 (en)
EP (1) EP1156797B1 (en)
JP (1) JP2002538200A (en)
KR (1) KR20020005615A (en)
CN (1) CN1208065C (en)
AT (1) ATE376445T1 (en)
AU (1) AU771510B2 (en)
BR (1) BR0008829A (en)
CA (1) CA2364251C (en)
CZ (1) CZ20013120A3 (en)
DE (1) DE60036862T2 (en)
HK (1) HK1041438B (en)
HU (1) HUP0200294A3 (en)
IL (1) IL145189A0 (en)
NO (1) NO20014347L (en)
NZ (2) NZ530747A (en)
PL (1) PL350660A1 (en)
RU (1) RU2251415C2 (en)
WO (1) WO2000053167A2 (en)
ZA (1) ZA200108283B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
WO2003032915A2 (en) * 2001-10-16 2003-04-24 Avanir Pharmacueticals Viral inhibition by n-docosanol
US7323453B2 (en) * 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
JP2008534602A (en) * 2005-03-30 2008-08-28 ノバルティス アクチエンゲゼルシャフト Penciclovir for treatment of recurrent genital herpes with daily application
US20080194518A1 (en) * 2005-12-23 2008-08-14 MOOKERJEE Pradip Antimicrobial Compositions
US20090312279A1 (en) * 2005-12-23 2009-12-17 Sterilex Technologies, Llc Antimicrobial compositions
US20070258996A1 (en) * 2005-12-23 2007-11-08 The Sterilex Corporation Antimicrobial compositions
JP2007182398A (en) * 2006-01-06 2007-07-19 Nakajima Kagaku Sangyo Kk Antiviral lubricant
US8236768B2 (en) 2008-10-03 2012-08-07 3B Pharmaceuticals, Inc. Topical antiviral formulations
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
WO2012174535A1 (en) * 2011-06-17 2012-12-20 Constitution Medical, Inc. Solutions for histoprocessing of biological samples
US9125911B2 (en) * 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
JP6125962B2 (en) * 2013-09-24 2017-05-10 株式会社デンソー Antiviral agent
US11071745B2 (en) * 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
FR3054454B1 (en) 2016-07-26 2020-04-10 IFP Energies Nouvelles CATALYST COMPRISING AN IZM-2 ZEOLITE HAVING AN OPTIMIZED IF / AL MOLAR RATIO FOR THE ISOMERIZATION OF C8 AROMATIC CUTS
FR3104458B1 (en) 2019-12-17 2022-01-07 Ifp Energies Now CATALYST BASED ON ZEOLITH IZM-2 HAVING A LOW ALKALINE CONTENT AND ITS USE FOR THE ISOMERIZATION OF THE AROMATIC C8 CUT
CN111743888B (en) * 2020-06-16 2021-10-22 广州医科大学附属第一医院 Application of (2Z,4E) -2, 4-decadienoic acid in preparing medicine for treating inflammation caused by influenza virus

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1109119A (en) * 1910-03-29 1914-09-01 Ellis Foster Co Solidified oil and process of making same.
US3031376A (en) * 1956-10-11 1962-04-24 Levin Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same
US3584115A (en) * 1968-05-31 1971-06-08 Arthur Ira Gebhart Method of applying visible aerosol compositions
US3592930A (en) 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US3946035A (en) 1972-06-29 1976-03-23 L'oreal Anti-inflammatory polymers, pharmaceutical compositions containing the same and process for producing said polymers
US4076799A (en) 1972-12-27 1978-02-28 Cincinnati Milacron, Inc. Method of inhibiting skin irritation
GB1459233A (en) 1973-08-29 1976-12-22 Inst Rech Chim Biolog Medicament containing a higher alkanol
US3987198A (en) 1973-10-16 1976-10-19 Syntex (U.S.A.) Inc. Method for lowering the free fatty acid content in sebum using certain fatty acid amides
GB1523865A (en) 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4025645A (en) 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
US4200655A (en) 1978-08-15 1980-04-29 Sterling Drug Inc. Benzyl alcohol virucidal process
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4670471A (en) 1981-11-03 1987-06-02 Clark Lealand L Treatment for inflammatory skin disease
GB2122610B (en) 1982-05-28 1987-04-01 Eisai Co Ltd A polyprenyl compound and a pharmaceutical composition containing a polyprenyl compound
AU546872B2 (en) 1982-06-16 1985-09-26 Unilever Plc Skin treatment compositions containing a fatty acid or ester
US4513008A (en) 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
DE3421468A1 (en) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
GB8602346D0 (en) 1986-01-30 1986-03-05 Wellcome Found Antiviral combinations
US5208257A (en) 1986-04-21 1993-05-04 Kabara Jon J Topical antimicrobial pharmaceutical compositions and methods
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4940586A (en) 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4865848A (en) 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4900555A (en) 1987-02-26 1990-02-13 Alza Corporation Skin permeation enhancer compositions using sucrose esters
IT1203934B (en) 1987-04-17 1989-02-23 Consiglio Nazionale Ricerche PHARMACEUTICAL COMPOSITIONS CONTAINING HIGHER ALCOHOLS FOR THE TREATMENT OF PROSTATE DISEASES
US5380754A (en) 1988-02-29 1995-01-10 Virotex Corporation Topical composition enhancing healing of viral lesions
US5135956A (en) 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
US5070107A (en) 1989-04-28 1991-12-03 Lidak Pharmaceuticals Systemic antiviral treatment
US5071879A (en) 1989-04-28 1991-12-10 Lidak Pharmaceuticals Systemic antiviral treatment
US4874794A (en) 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
US5104656A (en) 1989-06-16 1992-04-14 Seth Pyare L Percutaneous treatment with a high potency non-steroidal anti-inflammatory agent
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US4956171A (en) 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5194451A (en) 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
US5166219A (en) 1989-11-02 1992-11-24 Lidak Pharmaceuticals Systemic anti-inflammatory treatment
JPH03157349A (en) 1989-11-14 1991-07-05 Lion Corp Emulsified composition
ATE190497T1 (en) * 1990-08-23 2000-04-15 Chiron Corp USE OF RECOMBINANT COLONY-STIMULATING FACTOR-1
US5202125A (en) * 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5312837A (en) * 1991-01-29 1994-05-17 Genelabs Technologies, Inc. Method of treating viral infections with aryl macrocyclic compounds
DE4111105A1 (en) 1991-04-05 1992-10-08 Max Planck Gesellschaft NEW ERUCYL, BRASSIDYL AND NERVONYL DERIVATIVES
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
US5580571A (en) 1991-10-15 1996-12-03 Hostetler; Karl Y. Nucleoside analogues
IL105090A (en) * 1992-03-18 1998-08-16 Us Bioscience N-(phosphonoacetyl)-l-aspartic acid as broad spectrum antiviral
DK169121B1 (en) 1992-09-09 1994-08-22 Gea Farmaceutisk Fabrik As Antivirally active pharmaceutical oil-in-water emulsion containing 9 - [(2-hydroxyethoxy) methyl] guanine (acyclovir) or a salt or ester thereof
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
AU6018894A (en) 1993-01-15 1994-08-15 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
US5484911A (en) * 1993-04-01 1996-01-16 Health Research, Inc. Nucleoside 5'-diphosphate conjugates of ether lipids
JPH0717545U (en) * 1993-08-27 1995-03-28 南工学株式会社 Squeegee device for screen printing machine
PL174765B1 (en) 1993-09-10 1998-09-30 Recordati Chem Pharm Method of obtaining 9-(2-hydroxy)etyhoxymethylquanine
CN1103586C (en) 1993-12-13 2003-03-26 里达克药品公司 Sucrose ester C-zo to C-28 alcohol formulations
US5952004A (en) * 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
US5447729A (en) 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
DE4414755C2 (en) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Collagen preparation for the controlled delivery of active ingredients, processes and use
IL110380A0 (en) 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
US5567816A (en) 1994-07-26 1996-10-22 Syntex (U.S.A.) Inc. Preparation of acyclovir using 1,3 dioxolane
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US5883103A (en) 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
WO1997009978A1 (en) 1995-09-13 1997-03-20 Morten Sloth Weidner Use of esters of polyhydric alcohols to enhance the oral bioavailability of drug substances as well as novel esters and pharmaceutical compositions containing them
CA2231837A1 (en) 1995-09-13 1997-03-20 Florida State University Radiosensitizing taxanes and their pharmaceutical preparations
EP0871489A1 (en) 1995-10-12 1998-10-21 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CN1213748C (en) * 1996-09-17 2005-08-10 阿文尼尔药品公司 Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
US5952392A (en) * 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6440980B1 (en) 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
IT1287114B1 (en) * 1996-10-31 1998-08-04 Recordati Chem Pharm ANTI-HERPETIC PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATORS, CONTAINING ACICLOVIR
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
US5871763A (en) * 1997-04-24 1999-02-16 Fort James Corporation Substrate treated with lotion

Also Published As

Publication number Publication date
JP2002538200A (en) 2002-11-12
US7091190B2 (en) 2006-08-15
NO20014347D0 (en) 2001-09-06
ZA200108283B (en) 2002-08-28
PL350660A1 (en) 2003-01-27
EP1156797B1 (en) 2007-10-24
CN1424926A (en) 2003-06-18
US6440980B1 (en) 2002-08-27
US20030073651A1 (en) 2003-04-17
IL145189A0 (en) 2002-06-30
AU3396200A (en) 2000-09-28
ATE376445T1 (en) 2007-11-15
CN1208065C (en) 2005-06-29
DE60036862T2 (en) 2008-08-14
WO2000053167A2 (en) 2000-09-14
NO20014347L (en) 2001-10-05
AU771510B2 (en) 2004-03-25
BR0008829A (en) 2001-12-18
WO2000053167A3 (en) 2001-02-15
CZ20013120A3 (en) 2002-02-13
CA2364251C (en) 2004-11-02
RU2251415C2 (en) 2005-05-10
HK1041438B (en) 2008-05-09
HK1041438A1 (en) 2002-07-12
KR20020005615A (en) 2002-01-17
HUP0200294A2 (en) 2002-07-29
DE60036862D1 (en) 2007-12-06
NZ530747A (en) 2005-06-24
EP1156797A2 (en) 2001-11-28
NZ513849A (en) 2004-03-26
HUP0200294A3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
CA2364251A1 (en) Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
EP0707481A4 (en)
ES2161418T3 (en) PIRIDILFURAN AND PIRIDILTIOFENO COMPOUNDS AND PHARMACEUTICAL USE OF THEM.
CA2130755A1 (en) Intermediates useful in the preparation of purine nucleoside analogues
ZA9711607B (en) Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
ZA9711606B (en) Cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them.
HRP20031003A2 (en) 4'-substituted nukleosides
WO2003073989A3 (en) Nucleoside 5'-monophosphate mimics and their prodrugs
WO1998045259A3 (en) Polyaromatic antiviral compositions
MD1838G2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
AU7535798A (en) Novel cyclosporin derivatives, preparation and pharmaceutical compositions containing same
CA2168447A1 (en) Compounds and methods for inhibition of hiv and related viruses
NO20020931L (en) Pyrrolo [2,3-d] pyrimidine nucleoside analogs
ES8701193A1 (en) Griseolic acid derivatives, and their use.
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
CA2127472A1 (en) New adenosine derivatives, preparation methods and pharmaceutical compositions containing them
GR3024226T3 (en) Antiviral naphthoquinone compounds, compositions and uses thereof.
NO983444L (en) Benzo (c) quinolizine derivatives, their preparation and use as 5 <alfa> reductase inhibitors
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
AU7806187A (en) Sulphonamide derivatives for the treatment and prevention of viral diseases
CA2213099A1 (en) S-(+)-adenosylmethionine and 3'-azido-2',3'-dideoxy-nucleoside complexes as potent inhibitors of hiv-replication
NZ514425A (en) Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
AU567018B2 (en) Prazosin-pirbuterol combination for bronchoduation
WO2001051055A3 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
CA2152387A1 (en) Synergistic anti-viral compositions

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180308